Progress in Immuno-Oncology: Delivering Hope and Clinical Benefit to Cancer Patients
Wednesday, July 19, 2017 – Noon-1:30 p.m.
Russell Senate Office Building, Room 485 – U.S. Capitol Hill
One of the most promising areas of cancer research is the field of immuno-oncology. Scientists are discovering new ways to arm a patient’s immune system so that it can attack cancer cells, and the result has been one of the most transformative approaches to cancer treatment that has ever entered the clinic.
For many patients, cancer immunotherapies are already providing life-saving results where other treatments had failed or were not viable. But realizing more breakthroughs in this area and broadening the scope of cancers that can be treated with immuno-oncology requires a sustained, federal investment in cancer research through the National Institutes of Health and the National Cancer Institute.
The American Association for Cancer Research and the Society for Immunotherapy of Cancer were pleased to host a briefing that highlighted exciting innovations being delivered through immuno-oncology, illustrated the hope that these advances are bringing to patients and noting the challenges that still need to be overcome so more patients can benefit from these revolutionary treatments.
Briefing speakers included: Speakers for this Congressional briefing included: Lisa H. Butterfield, PhD – SITC President; Elizabeth A. Jaffee, MD, President-elect, AACR and Past SITC Board Member; Steven Rosenberg, MD, PhD, Chief of Surgery at the National Cancer Institute and Past SITC Board Member; Bernard A. Fox, PhD, Past SITC President; Chief, Molecular and Tumor Immunology, Earle A. Chiles Research Institute; Daniel Chen, MD, PhD, Vice President, Global Head of Cancer Immunotherapy Development, Genentech; Co-Chair of the SITC Industry Committee; and Stefanie Joho, cancer research and patient advocate.